linjc16/ctgov huggingface dataset:
Trends in Intellectual Development in Down Syndrome

Study Overview
=================
Brief Summary
-----------------
Previous foreign studies revealed that the IQ in Down syndrome (DS) declines with age, but not any investigation of domestic data in Taiwan was available. Individuals with DS are characterized by limited verbal development, and in this article, authors look into the diverging verbal-nonverbal abilities in the DS phenotype.

Detailed Description
-----------------
The present study investigated this by analysis the test results of development /intelligence scales. To compare initial cross-sectional data with longitudinal follow-up, about 12 people with DS were included.

Official Title
-----------------
Trends in Intellectual Development, and Diverging Verbal and Non-verbal Abilities in the Down Syndrome Phenotype

Conditions
-----------------
Down Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Down syndrome with psychological test results Exclusion Criteria: Comorbidity of severe Autism or visual/auditory impairment

Ages Eligible for Study
-----------------
Minimum Age: 3 Months
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| IQ trend<br>all subjects | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| IQ |  | 2001-2010 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| mental age |  | 2001-2010 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Down syndrome, IQ, mental age, neuropsychological function
Drug Therapy for Alcohol Dependence in Alaska Natives (Naltrexone/Sertraline)

Study Overview
=================
Brief Summary
-----------------
This study will assess the ability of naltrexone (Revia) to reduce the risk of relapse in Alaska natives with alcohol dependence. The study will also examine whether a combination of naltrexone and sertraline (Zoloft) yields better abstinence rates than naltrexone used alone. Alaska Native individuals will be recruited into a 16 week outpatient study.

Official Title
-----------------
Naltrexone and SSRI Therapy for Alcohol Dependence in Alaska Natives

Conditions
-----------------
Alcoholism, Alcohol Dependence

Intervention / Treatment
-----------------
* Drug: sertraline
* Drug: naltrexone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Alaska Native having biological Alaska Native ancestry. Meets criteria for alcohol dependence. Prior to entering the study must be abstinent between 3 and 14 days and have a withdrawal assessment. Stable residence to ensure that subjects can be located during the study. Exclusion Criteria: Currently meets criteria for abuse or dependence on substances other than alcohol or nicotine. Current use of disulfiram. Psychotic or otherwise severely psychiatrically disabled. Use of other psychotropic medications including antidepressants and anxiolytics. Medical conditions that would not permit the use of sertraline or naltrexone, such as a history of unstable or severe hepatic, cardiovascular, metabolic, endocrine, gastrointestinal or kidney disease. Hepatocellular disease or elevated bilirubin levels. Females who are pregnant, nursing, or not using a reliable method of birth control. Probation or parole requirements that might interfere with participation in the study. Involvement in alcohol treatment other than provided by the study or AA. Use of monoamine oxidase inhibitors in the past month. Current use of Type 1C antiarrhythmics propafenone and flecainide.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Naltrexone plus Sertraline | Drug: naltrexone<br>* 16 week outpatient study<br>* Other names: Revia;|
| Experimental: 2<br>Naltrexone alone | Drug: sertraline<br>* 16 week outpatient study<br>* Other names: Zoloft;Drug: naltrexone<br>* 16 week outpatient study<br>* Other names: Revia;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Days abstinent |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Alcoholism, Alcohol Dependence
SUV Max as Predictor of Outcome in Cervical Cancer

Study Overview
=================
Brief Summary
-----------------
Cervical Cancer is staged clinically, not surgically. Patients in whom an extensive disease is identified are not usually eligible for surgery. PET-CT is used to support staging. However, some patients received surgery after staging and subsequently require radio/chemotherapy due to findings on operation. This study will attempt to find a correlation between SUV-Max on PET-CT and subsequent outcomes i.e. need for adjuvant therapy.

Official Title
-----------------
A Study to Evaluate the Value of SUV-Max in PET-FDG in Predicting Outcome of Surgery Vis a Vis Need for Radiotherapy

Conditions
-----------------
Cervical Cancer

Intervention / Treatment
-----------------
* Radiation: Radiotherapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: having stating PET-CT stored on site treated with surgery Exclusion Criteria: not eligible for surgery based on PET-CT, clinical stage

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Case group<br> | Radiation: Radiotherapy<br>* Radiotherapy for cervical cancer<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Administration of adjuvant therapy |  | immediately following surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival |  | surgery - present day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cervical Cancer, PET CT, SUV Max
Rapid Structural and Functional Improvements in Following 0.19 mg Fluocinolone Acetonide (FAc) Implant in Diabetic Macular Edema Patients With Poor Visual Acuity: 12-month Audit Results From United Arab Emirates

Study Overview
=================
Brief Summary
-----------------
The Health Authority - Abu Dhabi (HAAD) approved the reimbursement of the slow release FAc implant (ILUVIEN) and it is now available for the treatment of diabetic macular edema (DME) in persons who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. We performed a retrospective 12-month audit to assess the efficacy and safety of the FAc implant in our clinical practice.

Detailed Description
-----------------
Twenty patients with pseudophakic lenses, treated with ILUVIEN, were investigated to evaluate functional and anatomical characteristics and outcomes (visual acuity [VA; ETDRS letters score], central macular thickness [CMT] and intraocular pressure [IOP]) at baseline, weeks 2-4 and months 3, 6 and 12 months.

Official Title
-----------------
Rapid Structural and Functional Improvements in Following 0.19 mg Fluocinolone Acetonide (FAc) Implant in Diabetic Macular Edema Patients With Poor Visual Acuity: 12-month Audit Results From United Arab Emirates

Conditions
-----------------
Diabetic Macular Edema

Intervention / Treatment
-----------------
* Drug: 0.19 mg fluocinolone acetonide (FAc) implant
* Device: 0.19 mg fluocinolone acetonide (FAc) implant


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: DME Pseudophakic Exclusion Criteria: Other causes of macular edema. Phakic Know case of gaucoma

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>patients treated with 0.19 mg fluocinolone acetonide (FAc) implant for 12 months | Drug: 0.19 mg fluocinolone acetonide (FAc) implant<br>* 0.19 mg fluocinolone acetonide (FAc) implant<br>Device: 0.19 mg fluocinolone acetonide (FAc) implant<br>* 0.19 mg fluocinolone acetonide (FAc) implant<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| BCVA | best corrected visual acuity | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CMT | Central Macular thickness | 12 months | 
| IOP | Intraocular pressure | 12 months |
Exercise Intervention in Liver Transplant Candidates

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to investigate the effect of personalised exercise interventions in liver transplant candidates, aiming to prevent or limit sarcopenia and frailty, as well as improving their cardiorespiratory health.

Official Title
-----------------
The Effect of a Personalised Training Programme on the Functional Ability and the Quality of Life of Candidates for Liver Transplantation

Conditions
-----------------
Liver Diseases

Intervention / Treatment
-----------------
* Behavioral: Personalised exercise


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Liver transplant candidates, accepted in the waiting list of the Surgical Department of Transplantation A.U.Th., General Hospital of Thessaloniki Ippokratio. Exclusion Criteria: Recent (<12 months) Acute Myocardial Infraction Recent (<12 months) brain strokes Uncontrolled and/or untreated arrythmia Hepatic encephalopathy Bed-bound patient Liver Transplantation Death

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Regular treatment<br> | |
| Experimental: Exercise Intervention<br> | Behavioral: Personalised exercise<br>* Personalised exercise intervention including aerobic and resistance training<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from Baseline Liver Frailty Index value at 12 weeks | A frailty index for patients with cirrhosis, comprised of three performance-based metrics | After 12-week exercise intervention | 
| Change from Baseline 6 Minute Walking Test value at 12 weeks | A walking test for patients to evaluate their functional capacity | After 12-week exercise intervention | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| VO2max | Maximum oxygen consumption during incremental exercise | Before intervention initiation and after 12-week exercise intervention |
Pleuropulmonary Echography Versus Standard Chest X-ray in the Post-operative Follow-up of Pleuropulmonary Surgery

Study Overview
=================
Brief Summary
-----------------
In postoperative pleuro-pulmonary surgery, the monitoring of the appearance of complications is guided, depending on the centres, by the systematic daily performance or, in the event of a call point, by chest x-ray at the patient's bed until the drains are ablative. This repeated performance of radiographs results in irradiation of patients but also of medical staff and a significant cost. In the thoracic study, ultrasound imaging is a fast, cost-effective, non-irradiating solution that can be performed at the patient's bedside. It could guide the performance of chest x-ray, limit their number, with increased clinical relevance.

Official Title
-----------------
Interest of Pleuropulmonary Echography Versus Standard Chest X-ray in the Post-operative Follow-up of Pleuropulmonary Surgery

Conditions
-----------------
Pleuro-pulmonary Surgery

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient with a higher age to 18 and undergoing pleuro-pulmonary surgery Hospitalized patient at Martinique University Hospital Patient receiving social security Patient giving his free and informed consent orally Exclusion Criteria: Patient minor Woman who is pregnant and breast feeding Patient no giving his free and informed consent orally

Ages Eligible for Study
-----------------
Minimum Age: 18 Months

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of pleural disorders identified by each imaging technique | Number | between 2 and 10 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of ultrasounds performed/number of chest x-ray performed | Ratio | one year | 
| Proportion of negative ultrasounds | Number | one year |
Phase I Study to Determine the Maximum Tolerate Dose (MTD) of BGT226 in Advanced Solid Tumors in Japan

Study Overview
=================
Brief Summary
-----------------
This study will confirm safety and tolerability and determine the MTD of BGT226 in Japanese patients with advanced solid tumor.

Official Title
-----------------
A Phase I Study of BGT226, Administered Orally in Adult Patients With Advanced Solid Tumor in Japan

Conditions
-----------------
Cancer, Solid Tumor, Advanced Solid Tumor

Intervention / Treatment
-----------------
* Drug: BGT226


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: World Health Organization (WHO) Performance Status of ≤ 2 Histologically-confirmed, advanced solid tumors Progressive, recurrent unresectable disease Age ≥ 20 Exclusion Criteria: Hematopoietic: No diabetes mellitus or history of gestational diabetes mellitus No acute or chronic renal disease No acute or chronic liver disease No acute or chronic pancreatitis No impaired cardiac function or clinically significant cardiac diseases such as ventricular arrhythmia, congestive heart failure, uncontrolled hypertension No acute myocardial infarction or unstable angina pectoris within the past 3 months Not pregnant or nursing and fertile patients must use barrier contraceptives Other protocol-defined inclusion/exclusion criteria may apply.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: BGT226<br> | Drug: BGT226<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of dose limiting toxicity (DLT) at each dose level |  | 22-28 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety measured by type, frequency and severity of adverse drug reactions | Safety measures by Common Terminology Criteria for Adverse Events (CTCAE) | Every 4 weeks | 
| Preliminary Efficacy od BGT226 | Measured by Response Evaluation criteria in Solid Tumors (RECIST) | Every 8 weeks | 
| Percent of patients in which an altered molecular status is detected for markers related to Pl3K signaling |  | Baseline, every 3 weeks | 
| Biomarkers: Percentage of change, pre- versus post-treatment |  | Every month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PI3K, mTOR, Advanced solid tumor, Adult
DANish Multicenter STENT Trial

Study Overview
=================
Brief Summary
-----------------
The purpose of the study was to evaluate procedural and late outcome of coronary artery stenting using 2 different unmounted stents

Official Title
-----------------
Low Restenosis Rate of the NIR Coronary Stent: Results of the Danish Multicenter Stent Study (DANSTENT) - a Randomized Study Comparing a First-Generation With a Second-Generation Stent.

Conditions
-----------------
Ischemic Heart Disease, Stable Angina, Unstable Angina

Intervention / Treatment
-----------------
* Device: Coronary Stent Implantation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Stable, unstable or silent angina, De novo lesion Exclusion Criteria: Allergy to ticlopidine Recent myocardial infarction Expected survival > 1 year

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Coronary Stent Implantation|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Trapezoidal Flap vs. Envelope Flap in Mandibular Third Molar Extraction.

Study Overview
=================
Brief Summary
-----------------
the purpose of this study was to test the effectiveness of the envelope flap compared to trapezoidal flap in impacted mandibular third molar extractions.

Detailed Description
-----------------
a sample of 50 patients requiring mandibular third molar extraction was selected for the study. Healthy patients with mild symptoms of pericoronitis affecting at least 1 mandibular third molar were included in the study. A total number of 52 consecutive cases of mandibular third molar surgical extractions were performed using either a trapezoidal flap or an envelope flap. The choice of the flap was randomized. The following parameters were recorded: Probing Pocket Depth, Clinical Attachment Level, Bleeding on Probing, Full Mouth Plaque Score, Full Mouth Bleeding Score, total time for the surgical intervention, age of the patient, type of inclusion, ostectomy. All the patients received a questionnaire to evaluate the post-intervention discomfort (swelling, pain, number of pain-killers, bleeding). Periodontal parameters were checked at 6-month follow up.

Official Title
-----------------
Trapezoidal Flap Versus Envelope Flap in Impacted Mandibular Third Molar Extraction

Conditions
-----------------
Impacted Third Molar Tooth

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: third molar impaction mild symptoms of pericoronitis Exclusion Criteria: systemic diseases cigarettes smoking history of irradiation therapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| test envelope<br>envelope flap | |
| control, trapezodal<br>standard incision | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change from baseline on the periodontal status of adjacent second molar |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| post surgical complication |  | 2 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
third molar surgery, periodontal probing depth , flap design
Cardiac Outcome Measures in Children With Muscular Dystrophy

Study Overview
=================
Brief Summary
-----------------
The purpose of the research study is to evaluate different cardiac measures that are obtained by echocardiographic tests in patients with muscular dystrophy.

Detailed Description
-----------------
The research study will include 50 participants aged 8 to 18 years old (before 18th birthday) with Duchenne, Becker, or autosomal recessive limb-girdle (specifically: LGMD 2C-2F and 2I) muscular dystrophies. Participants will be seen in one of five Cooperative International Neuromuscular Research Group (CINRG) centers located in the United States. All study assessments will be completed in the same day and include reviewing past medical and surgical history, collecting vital signs, collecting cardiac measures through echocardiographic tests.

Official Title
-----------------
PITT1109: Cardiac Outcome Measures in Children With Muscular Dystrophy

Conditions
-----------------
Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Limb Girdle Muscular Dystrophy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participants must be between the ages of 8 and 18 years old Confirmed diagnosis of muscular dystrophy (DMD, BMD, or LGMD 2C-2F and 2I) Exclusion Criteria: Investigator assessment of inability to comply with protocol History of a congenital cardiac defect or other cardiac disease unrelated to muscular dystrophy

Ages Eligible for Study
-----------------
Minimum Age: 8 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cardiac, Muscular Dystrophy, Prospective, Pediatric, Echocardiogram